Rebecca Ahrens Nicklas Shares FDA Interactions on Interventional Genetics with The Rare Disease Community
Rebecca Ahrens Nicklas, Rare disease physician-scientist at the Children’s Hospital of Philadelphia, shared on LinkedIn:
”Excited to share our vision for how we scale personalized gene editing therapies.
We need formal clinical trials to critically evaluate these novel treatments and (hopefully) obtain formal approvals.
One major step to make this happen is regulatory innovation.
We thought it was essential that we share our FDA interactions with the rare disease community so that we can all learn together about how we will build the field of interventional genetics.”
Read the full article in AJHG.
Article: How to create personalized gene editing platforms: Next steps toward interventional genetics
Authors: Rebecca Ahrens Nicklas, Kiran Musunuru
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 12, 2026, 17:34Caitlin Raymond: Granulocyte Transfusions for the Overworked Fellow
-
Apr 12, 2026, 17:33Augustina Isioma Ikusemoro: ABO Typing Is Not the Same in Infants and Adults
-
Apr 12, 2026, 17:32Bastu Odoka: Same Blood Group Does Not Guarantee Compatibility
-
Apr 12, 2026, 17:31Jack Hadfield: SARS-CoV-2–Associated Lasting Mitochondrial Injury in Cardiomyocytes
-
Apr 12, 2026, 17:30Flora Peyvandi: ABB Milan Presentations During the ISTH 2026
-
Apr 12, 2026, 17:01Hafiz Saad Ullah: Introducing to Fully Automatic Peripheral Blood Smear Stainer
-
Apr 12, 2026, 16:53Najmul Hasan Forhad: A Simple Framework for Mastering Anticoagulant Therapy
-
Apr 12, 2026, 16:36Piotr Czempik: Patient Blood Management Means Safer Care, Better Quality, and Responsible Resource Use
-
Apr 12, 2026, 16:31Eishi Asano: Available Evidence and Unmet Needs in EEG Use During Stroke Management